AR041190A1 - Composicion y actividad antiviral de derivados de piperazina azaindoloxoacetico sustituidas - Google Patents
Composicion y actividad antiviral de derivados de piperazina azaindoloxoacetico sustituidasInfo
- Publication number
- AR041190A1 AR041190A1 ARP030102835A ARP030102835A AR041190A1 AR 041190 A1 AR041190 A1 AR 041190A1 AR P030102835 A ARP030102835 A AR P030102835A AR P030102835 A ARP030102835 A AR P030102835A AR 041190 A1 AR041190 A1 AR 041190A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- heteroaryl
- aryl
- heteroalicyclic
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 25
- 125000003118 aryl group Chemical group 0.000 abstract 23
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 21
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 18
- 229910052736 halogen Inorganic materials 0.000 abstract 15
- 150000002367 halogens Chemical class 0.000 abstract 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 10
- 125000002950 monocyclic group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 7
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 7
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 7
- 125000006413 ring segment Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 5
- -1 anti-infectives Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 229960005475 antiinfective agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 239000002835 hiv fusion inhibitor Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 abstract 1
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente, provee compuestos que poseen propiedades farmacológicas y de bio-afectación, sus composiciones farmacéuticas y método de uso. En particular, la invención se refiere a derivados de azaindoloxoacetilpiperazina. Estos compuestos ejercen una actividad exclusiva, ya sea cuando se los usa solos o en combinación con otros antivirales, anti-infecciosos, inmunomoduladores o inhibidores de la entrada del VIH. Más específicamente, la presente se refiere al tratamiento del VIH y SIDA Reivindicación 1: Un compuesto de fórmula (1), que incluye sus sales farmacéuticamente aceptables, caracterizado porque: Q es seleccionado del grupo integrado por las estructuras (2), donde R1, R2, R3 y R4, son independientemente seleccionados del grupo integrado por hidrógeno, halógeno, ciano, nitro, COOR56, XR57, C(O)R7, C(O)NR55R56, B, D, y E siempre y cuando, al menos uno entre R1-R4 sea seleccionado entre B o E; donde la linea punteada representa un enlace carbono-carbono o no existe; m es 1 o 2; R5 es hidrógeno o (CH2)nCH3, -C(O)(CH2)nCH3, -C(O)O(CH2)nCH3s, -C(O)(CH2)nN(CH3)2 donde n es 0-5; R6 es O o no existe; A es seleccionado del grupo integrado por C1-6alcoxi, arilo y heteroarilo; donde dicho arilo es fenilo o naftilo; dicho heteroarilo seleccionado del grupo integrado por piridinilo, pirimidinilo, pirazinilo, triazinilo, furanilo, tienilo, pirrolilo, imidazolilo, tiazolilo, isotiazolilo, oxazolilo, isoxazolilo, quinolinilo, isoquinolinilo, benzofuranilo, benzotienilo, benzoimidazolilo y benzotiazolilo; y dicho arilo o heteroarilo es opcionalmente substituido con uno o dos miembros iguales o diferentes seleccionados del grupo integrado por amino, nitro, ciano, hidroxi, C1-6alcoxi, -C(O)NH2, C1-6alquilo, -NHC(O)CH3, halógeno y trifluorometilo; -W- es de fórmula (3), B es seleccionado del grupo integrado por -C(=NR46)(R47), C(O)NR40R41, arilo, heteroarilo, heteroalicíclico, S(O)2R8, C(O)R7, XR8a, alquilo C1-6NR40R41, alquilo C1-6COOR8b; donde dicho arilo, heteroarilo, y heteroalicíclico son opcionalmente substituidos con uno a tres halógenos iguales o diferentes o entre uno a tres substituyentes iguales o diferentes seleccionados del grupo F; donde arilo es naftilo o fenilo substituido; donde heteroarilo es un sistema mono o bicíclico que contiene entre 3 y 7 átomos anulares para un sistema monocíclico y hasta 12 átomos en un sistema bicíclico fusionado, que incluye entre 1 y 4 heteroátomos; donde heteroalicíclico es un anillo monocíclico de 3 a 7 miembros que puede contener entre 1 y 2 heteroátomos en el esqueleto del anillo y que puede fusionarse a un anillo de benceno o piridina; q es 0, 1, o 2; D es seleccionado del grupo integrado por alquilo C1-6 y alquenilo C2-6; donde dicho alquilo C1-6 y alquenilo C2-6 están opcionalmente substituidos con uno a tres halógenos iguales o diferentes o entre uno y tres substituyentes seleccionados del grupo integrado por C(O)NR55R56, hidroxi, ciano y XR57; E es seleccionado del grupo integrado por alquilo C1-6 y alquenilo C2-6; donde dicho alquilo C1-6 y alquenilo C2-6 están opcional e independientemente substituidos con un miembro seleccionado del grupo integrado por fenilo, heteroarilo, SMe, SPh, -C(O)NR56R57, C(O)R57, SO2alquilo C1-6 y SO2Ph; donde heteroarilo es un sistema monocíclico que contiene entre 3 y 7 átomos anulares, que incluye entre 1 y 4 heteroátomos; F es seleccionado del grupo integrado por alquilo, cicloalquilo, arilo, heteroarilo, heteroalicíclico, hidroxi, alcoxi C1-6, ariloxi, tioalcoxi C1-6, ciano, halógeno, nitro, -C(O)R57, bencilo, -NR42C(O)-alquilo C1-6, -NR42C(O)-cicloalquilo C3-6, -NR42C(O)-arilo, -NR42C(O)-heteroarilo, -NR42C(O)-heteroalicíclico, un anillo cíclico de N-lactama de 4, 5, o 6 miembros, -NR42S(O)2-alquilo C1-6, -NR42S(O)2-cicloalquilo C3-6, -NR42S(O)2-arilo, -NR42S(O)2-heteroarilo, -NR42S(O)2-heteroalicíclico, S(O)2alquilo C1-6, S(O)2arilo,-S(O)2NR42R43, NR42R43, alquilo C1-6C(O)NR42R43, C(O)NR42R43, NHC(O)NR42R43, OC(O)NR42R43, NHC(O)OR54, alquilo C1-6NR42R43, COOR54, y alquilo C1-6COOR54; donde dicho alquilo C1-6, cicloalquilo C3-7, arilo, heteroarilo, heteroalicíclico, alcoxi C1-6, y ariloxi, están opcionalmente substituidos con uno a nueve halógenos iguales o diferentes o entre uno y cinco substituyentes iguales o diferentes seleccionados del grupo G; donde arilo es fenilo; heteroarilo es un sistema monocíclico que contiene entre 3 y 7 átomos anulares, que incluye entre 1 y 4 heteroátomos; heteroalicíclico es seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, piperidina, tetrahidrofurano, tetrahidropirano, azepina, y morfolina; G es seleccionado del grupo integrado por alquilo C1-6, cicloalquilo C3-7, arilo, heteroarilo, heteroalicíclico, hidroxi, alcoxi C1-6, ariloxi, ciano, halógeno, nitro, -C(O)R57, bencilo, -NR48C(O)-alquilo C1-6, -NR48C(O)-cicloalquilo C3-6, -NR48C(-O)-arilo, -NR48C(O)-heteroarilo, -NR48C(O)-heteroalicíclico, un anillo cíclico de N-lactama de 4, 5, o 6 miembros, -NR48S(O)2-alquilo C1-6, -NR48S(O)2-cicloalquilo C3-6, -NR48S(O)2-arilo, -NR48S(O)2-heteroarilo, -NR48S(O)2-heteroalicíclico, sulfinilo, sulfonilo, sulfonamida, NR48R49, alquilo C1-6C(O)NR48R49, C(O)NR48R49, NHC(O)NR48R49, OC(O)NR48R49, NHC(O)OR54', alquilo C1-6NR48R49, COOR54, y alquilo COOR54; donde arilo es fenilo; heteroarilo es un sistema monocíclico que contiene entre 3 y 7 átomos anulares, que incluye entre 1 y 4 heteroátomos; heteroalicíclico es seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, piperidina, tetrahidrofurano, tetrahidropirano, azepina, y morfolina; R7 es seleccionado del grupo integrado por arilo, heteroarilo, heteroalicíclico; donde dicho arilo, heteroarilo, y heteroalicíclico son opcionalmente substituidos con uno a tres halógenos iguales o diferentes o entre uno a tres substituyentes iguales o diferentes seleccionados del grupo F; donde para R7, R8, R8a, R8b arilo es fenilo; heteroarilo es un sistema mono o bicíclico que contiene entre 3 y 7 átomos anulares para un sistema monocíclico y hasta 10 átomos en un sistema bicíclico, que incluye entre 1 y 4 heteroátomos; donde heteroalicíclico es seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, piperidina, tetrahidrofurano, tetrahidropirano, azepina, y morfolina; R8 es seleccionado del grupo integrado por hidrógeno, alquilo C1-6, cicloalquilo C3-7, alquenilo C2-6, cicloalquenilo C3-7, alquinilo C2-6, arilo, heteroarilo, y heteroalicíclico; donde dicho alquilo C1-6, cicloalquilo C3-7, alquenilo C2-6, cicloalquenilo C3-7, alquinilo C2-6, arilo, heteroarilo, y heteroalicíclico están opcionalmente substituidos con uno a seis halógenos iguales o diferentes o entre uno y cinco substituyentes iguales o diferentes seleccionado del grupo F; R8a es un miembro seleccionado del grupo integrado por arilo, heteroarilo, heteroalicíclico; donde cada miembro está opcional e independientemente substituido con uno a seis halógenos iguales o diferentes o entre uno y cinco substituyentes iguales o diferentes seleccionados del grupo F; R8b es seleccionado del grupo integrado por hidrógeno, alquilo C1-6 y fenilo; R9, R10, R11, R12, R13, R14, R15, R16, son independientemente seleccionados del grupo integrado por hidrógeno y alquilo; donde dicho alquilo está opcionalmente substituido con uno a tres halógenos iguales o diferentes; X es seleccionado del grupo integrado por NH o NCH3, O, y S; R40 y R41 son independientemente seleccionado del grupo integrado por (a) hidrógeno; (b) alquilo C1-6 o cicloalquilo C3-7 substituido con uno a tres halógenos iguales o diferentes o entre uno y dos substituyentes iguales o diferentes seleccionados del grupo F; y (c) alcoxi C1-6, arilo, heteroarilo o heteroalicíclico; o R40 y R41 tomados en conjunto con el nitrógeno al cual se unen forman un miembro seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, 4-NMe piperazina, piperidina, azepina, y morfolina; y donde dicho arilo, heteroarilo, y heteroalicíclico son opcionalmente substituidos con uno a tres halógenos iguales o diferentes o entre uno y dos substituyentes iguales o diferentes seleccionados del grupo F; donde para R40 y R41 arilo es fenilo; heteroarilo es un sistema monocíclico que contiene entre 3 y 6 átomos anulares, que incluye entre 1 y 4 heteroátomos; heteroalicíclico es seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, piperidina, tetrahidrofurano, tetrahidropirano, azepina, y morfolina; con la condición que cuando B sea C(O)NR40R41, al menos uno, R40 o R41 no sea seleccionado entre los grupos (a) o (b); R42 y R43 son independientemente seleccionado del grupo integrado por hidrógeno, alquilo C1-6, alilo, alcoxi C1-6, cicloalquilo C3-7, arilo, heteroarilo y heteroalicíclico; o R42 y R43 tomados en conjunto con el nitrógeno al cual se unen forman un miembro seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, 4-NMe piperazina, piperidina, azepina, y morfolina; y donde dicho alquilo C1-6, alcoxi C1-6, cicloalquilo C3-7, arilo, heteroarilo, y heteroalicíclico están opcionalmente substituidos con uno a tres halógenos iguales o diferentes o entre uno y dos substituyentes iguales o diferentes seleccionados del grupo G; donde para R42 y R43 arilo es fenilo; heteroarilo es un sistema monocíclico que contiene entre 3 y 6 átomos anulares, que incluye entre 1 y 4 heteroátomos; heteroalicíclico es un miembro seleccionado del grupo integrado por aziridina, azetidina, pirrolidina, piperazina, piperidina, tetrahidrofurano, tetrahidropirano, azepina, y morfolina; Ra y Rb son independientemente H, alquilo C1-6 o fenilo; R46 es seleccionado del grupo integrado por H, OR57, y NR55R56; R47 es seleccionado del grupo integrado por H, amino, halógeno, fenilo, y alquilo; R48 y R49 son independientemente seleccionado del grupo integrado por hidrógeno, alquilo y fenilo; R50 es seleccionado del grupo integrado por H, alquilo C1-6, cicloalquilo C3-6,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/214,982 US20030207910A1 (en) | 2001-02-02 | 2002-08-07 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041190A1 true AR041190A1 (es) | 2005-05-04 |
Family
ID=31714265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102835A AR041190A1 (es) | 2002-08-07 | 2003-08-07 | Composicion y actividad antiviral de derivados de piperazina azaindoloxoacetico sustituidas |
Country Status (31)
Country | Link |
---|---|
US (1) | US20030207910A1 (es) |
EP (4) | EP2497770B1 (es) |
KR (1) | KR101045154B1 (es) |
CN (2) | CN101229164B (es) |
AR (1) | AR041190A1 (es) |
AU (2) | AU2003261367B2 (es) |
BR (1) | BRPI0313286B8 (es) |
CA (1) | CA2494832C (es) |
CY (3) | CY1113413T1 (es) |
DK (3) | DK2801576T3 (es) |
ES (4) | ES2560844T3 (es) |
GE (1) | GEP20084284B (es) |
HK (4) | HK1174037A1 (es) |
HR (1) | HRP20050123B8 (es) |
HU (1) | HUE027396T2 (es) |
IL (1) | IL166512A (es) |
IS (1) | IS2919B (es) |
MX (1) | MXPA05001441A (es) |
MY (1) | MY146549A (es) |
NO (1) | NO331591B1 (es) |
NZ (1) | NZ537930A (es) |
PE (1) | PE20040772A1 (es) |
PL (1) | PL219566B1 (es) |
PT (3) | PT2497770E (es) |
RS (1) | RS53428B (es) |
RU (1) | RU2325389C2 (es) |
SI (3) | SI2801576T1 (es) |
TW (1) | TWI328452B (es) |
UA (1) | UA82199C2 (es) |
WO (1) | WO2004014380A1 (es) |
ZA (1) | ZA200501018B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0307834D0 (en) * | 2003-04-04 | 2003-05-14 | Ta Contrast Ab | Composition |
US20050075364A1 (en) * | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
US20050124623A1 (en) * | 2003-11-26 | 2005-06-09 | Bender John A. | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
DE602005010698D1 (de) | 2004-06-09 | 2008-12-11 | Glaxo Group Ltd | Pyrrolopyridinderivate |
US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
US7183284B2 (en) * | 2004-12-29 | 2007-02-27 | Bristol-Myers Squibb Company | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents |
US7601715B2 (en) | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
US7598380B2 (en) * | 2005-08-03 | 2009-10-06 | Bristol-Myers Squibb Company | Method of preparation of azaindole derivatives |
US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
US7504399B2 (en) * | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
US8318941B2 (en) * | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2346508B1 (en) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
WO2012019003A1 (en) * | 2010-08-06 | 2012-02-09 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
ES2585396T3 (es) * | 2010-12-02 | 2016-10-05 | VIIV Healthcare UK (No.5) Limited | Alquilamidas como inhibidores de la unión del VIH |
CN102718692B (zh) * | 2012-07-03 | 2014-01-08 | 苏州和健医药科技有限公司 | 一种7位甲基-5位氧取代吲哚化合物的制备方法 |
WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
EP3194387B1 (en) * | 2014-09-17 | 2019-07-31 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CA2983927A1 (en) | 2015-05-06 | 2016-11-10 | The Regents Of The University Of California | K-ras modulators |
EP4340839A1 (fr) * | 2021-05-21 | 2024-03-27 | Centre National de la Recherche Scientifique (CNRS) | Nouveaux derives azaindole en tant qu'agents antiviraux |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2761201A (en) | 1952-05-02 | 1956-09-04 | Griffin Wheel Co | Renewing molds |
US3830602A (en) | 1973-03-14 | 1974-08-20 | Commercial Shearing | Rotary pumps and motors |
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
IL99843A0 (en) | 1990-11-01 | 1992-08-18 | Merck & Co Inc | Synergistic combination of hiv reverse transcriptase inhibitors |
US5811432A (en) | 1990-11-09 | 1998-09-22 | Pfizer Inc | Azaoxindole derivatives |
JP3119485B2 (ja) | 1991-07-03 | 2000-12-18 | ファルマシア・アンド・アップジョン・カンパニー | 抗−エイズ薬としての置換インドール類 |
US5124327A (en) * | 1991-09-06 | 1992-06-23 | Merck & Co., Inc. | HIV reverse transcriptase |
WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
IT1265057B1 (it) | 1993-08-05 | 1996-10-28 | Dompe Spa | Tropil 7-azaindolil-3-carbossiamidi |
US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
IL146309A0 (en) | 1999-05-21 | 2002-07-25 | Scios Inc | Indole-type derivatives as inhibitors of p38 kinase |
US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
ES2250422T3 (es) | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
US6403211B1 (en) | 2000-07-18 | 2002-06-11 | 3M Innovative Properties Company | Liquid crystal polymer for flexible circuits |
EE05424B1 (et) * | 2001-02-02 | 2011-06-15 | Bristol-Myers Squibb Company | Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis |
AU2003217604A1 (en) * | 2002-02-23 | 2003-09-09 | Bristol-Myers Squibb Company | Method of treating hiv infection by preventing interaction of cd4 and gp120 |
-
2002
- 2002-08-07 US US10/214,982 patent/US20030207910A1/en not_active Abandoned
-
2003
- 2003-05-08 UA UAA200502051A patent/UA82199C2/uk unknown
- 2003-08-04 RS YU20050108A patent/RS53428B/en unknown
- 2003-08-04 CN CN2008100099420A patent/CN101229164B/zh not_active Expired - Lifetime
- 2003-08-04 CN CNB038237431A patent/CN100379421C/zh not_active Expired - Lifetime
- 2003-08-04 MX MXPA05001441A patent/MXPA05001441A/es active IP Right Grant
- 2003-08-04 RU RU2005106350/04A patent/RU2325389C2/ru active
- 2003-08-04 NZ NZ537930A patent/NZ537930A/en not_active IP Right Cessation
- 2003-08-05 ES ES14164659.6T patent/ES2560844T3/es not_active Expired - Lifetime
- 2003-08-05 ES ES03784906T patent/ES2388919T3/es not_active Expired - Lifetime
- 2003-08-05 PL PL375360A patent/PL219566B1/pl unknown
- 2003-08-05 CA CA2494832A patent/CA2494832C/en not_active Expired - Lifetime
- 2003-08-05 EP EP12170639.4A patent/EP2497770B1/en not_active Expired - Lifetime
- 2003-08-05 KR KR1020057002158A patent/KR101045154B1/ko active IP Right Grant
- 2003-08-05 SI SI200332464T patent/SI2801576T1/sl unknown
- 2003-08-05 PT PT121706394T patent/PT2497770E/pt unknown
- 2003-08-05 GE GEAP20038674A patent/GEP20084284B/en unknown
- 2003-08-05 SI SI200332192T patent/SI1549313T1/sl unknown
- 2003-08-05 DK DK14164659.6T patent/DK2801576T3/en active
- 2003-08-05 BR BRPI0313286A patent/BRPI0313286B8/pt active IP Right Grant
- 2003-08-05 SI SI200332361T patent/SI2497770T1/sl unknown
- 2003-08-05 ES ES15180409.3T patent/ES2641893T3/es not_active Expired - Lifetime
- 2003-08-05 EP EP15180409.3A patent/EP2975038B1/en not_active Expired - Lifetime
- 2003-08-05 EP EP03784906A patent/EP1549313B9/en not_active Expired - Lifetime
- 2003-08-05 PT PT141646596T patent/PT2801576E/pt unknown
- 2003-08-05 ES ES12170639.4T patent/ES2481044T3/es not_active Expired - Lifetime
- 2003-08-05 EP EP14164659.6A patent/EP2801576B1/en not_active Expired - Lifetime
- 2003-08-05 AU AU2003261367A patent/AU2003261367B2/en not_active Ceased
- 2003-08-05 PT PT03784906T patent/PT1549313E/pt unknown
- 2003-08-05 TW TW092121422A patent/TWI328452B/zh not_active IP Right Cessation
- 2003-08-05 DK DK12170639.4T patent/DK2497770T3/da active
- 2003-08-05 HU HUE14164659A patent/HUE027396T2/en unknown
- 2003-08-05 WO PCT/US2003/024415 patent/WO2004014380A1/en active Search and Examination
- 2003-08-05 DK DK03784906.4T patent/DK1549313T3/da active
- 2003-08-07 AR ARP030102835A patent/AR041190A1/es active IP Right Grant
- 2003-08-07 MY MYPI20033007A patent/MY146549A/en unknown
- 2003-08-07 PE PE2003000789A patent/PE20040772A1/es active IP Right Grant
-
2005
- 2005-01-26 IL IL166512A patent/IL166512A/en active IP Right Grant
- 2005-01-28 NO NO20050514A patent/NO331591B1/no not_active IP Right Cessation
- 2005-02-01 IS IS7682A patent/IS2919B/is unknown
- 2005-02-03 ZA ZA200501018A patent/ZA200501018B/en unknown
- 2005-02-07 HR HRP20050123AA patent/HRP20050123B8/hr not_active IP Right Cessation
- 2005-07-27 HK HK13101431.0A patent/HK1174037A1/xx not_active IP Right Cessation
- 2005-07-27 HK HK05106424.8A patent/HK1072731A1/xx not_active IP Right Cessation
-
2009
- 2009-06-12 AU AU2009202361A patent/AU2009202361B2/en not_active Ceased
-
2012
- 2012-08-21 CY CY20121100745T patent/CY1113413T1/el unknown
-
2014
- 2014-07-31 CY CY20141100578T patent/CY1115580T1/el unknown
-
2015
- 2015-03-23 HK HK15102916.0A patent/HK1202530A1/xx not_active IP Right Cessation
-
2016
- 2016-02-26 CY CY20161100162T patent/CY1117217T1/el unknown
- 2016-07-12 HK HK16108137.9A patent/HK1220181A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041190A1 (es) | Composicion y actividad antiviral de derivados de piperazina azaindoloxoacetico sustituidas | |
AR046920A1 (es) | Hidroxamatos conectados a acilurea y conectado a sulfonilurea | |
AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
AR064345A1 (es) | Derivados de 8-oxoadenina | |
EA200501617A1 (ru) | Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы | |
AR057979A1 (es) | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. | |
HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
AR025884A1 (es) | Compuestos de amina ciclica, su produccion y su uso | |
AR061651A1 (es) | Analogos de piridina ii | |
AR055801A1 (es) | Derivados de piperazina azaindoloxoacetica sustituida, forma cristalina del derivado 1,2,3-triazol, procesos de preparacion de los mismos y composiciones farmaceuticas que los contienen | |
AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
MD3820873T2 (ro) | Degradanți selectivi ai receptorului estrogen | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR038172A1 (es) | Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento | |
HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
AR041672A1 (es) | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo | |
AR048042A1 (es) | Inhibidores no nucleosidos de transcriptasa inversa y composiciones farmaceuticas | |
PE20001303A1 (es) | Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |